TEMPE, Ariz.–(BUSINESS WIRE)–iMetabolic Biopharma Corporation (iMBP) announces expansion of its strategic partnership relationship with Ligand Pharmaceuticals, building on an earlier alliance agreement initiated in 2018, giving access to Ligand’s OmniAb platform. Continue reading
Author Archive: AZBio
AZBio Career Center Launches Expanded Career Planning Portal
The Career Planning Portal by YM Careers®, a component of the AZBio Career Center that allows AZBio Members to create an account and access tools for researching, planning and developing their careers for years to come!Continue reading
Rockefeller Foundation’s third National Covid-19 Testing Action Plan calls on the U.S. government to massively scale up Covid-19 testing
Rockefeller Foundation’s third National Covid-19 Testing Action Plan calls on the U.S. government to massively scale up Covid-19 testing an lays out a new plan for the largest domestic testing scale up to date and proposes 14 executive actions for the current and incoming administrations to take in order to rapidly alter the trajectory of the pandemic in the United States. Testing all U.S. public K-12 public schools would cost $42.5 billion, or $8.5 billion per month for the remainder of the school year from February to June 2021.Continue reading
Opportunity Alert – Applications for TGen’s Summer Program are Now Open
Helios Scholars at TGen offers students full-time, paid internship opportunities that include research experience and professional development in the field of biomedical research.Continue reading
Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19
- U.S. FDA authorizes COVID-19 mRNA vaccine for emergency use; companies are prepared to deliver first doses in the U.S. immediately
- Pfizer and BioNTech previously announced an agreement with the U.S. Government to supply doses in 2020 & 2021
In collaboration with Operation Warp Speed, Pfizer and BioNTech, as well as other vaccine companies are expected to deliver hundreds of millions of vaccine doses to Americans by the end of 2021 - Historic science-driven efforts will seek to help bring an end to the most devastating pandemic in a century
- Pfizer and BioNTech expect to file a Biologics License Application for possible full regulatory approval in 2021
AZBio Celebrates Trailblazers in 2020
Each year, AZBio looks back across the legislative session to identify those leaders whose actions and active engagement support the growth of Arizona’s life science and healthcare industry and help to ensure the people of Arizona benefit from its success. Scores are then tallied and the top ten legislative leaders are named the year’s Trailblazers.Continue reading
NIH’s All of Us Research Program returns first genetic results to participants
The All of Us Research Program offers participants the opportunity to receive information back about their DNA. NIH
The National Institutes of Health’s All of Us Research Program has begun to return genetic results to participants who have donated biosamples for research. This reflects the program’s priority to give back information to its research volunteers. Initially, participants can choose to receive information about their genetic ancestry and traits, with health-related results available at a later date.Continue reading
HTG Announces an Early Access Program for its Prototype Whole Transcriptome Panel
TUCSON, Ariz., Dec. 08, 2020 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has launched an Early Access Program for its whole transcriptome panel using the HTG EdgeSeq technology. The Early Access Program is intended to allow select customers access to the panel in their laboratories or through services to be performed in our development laboratory prior to commercial launch of this product.Continue reading
Aqualung Therapeutics Corp. Publication Supports eNAMPT as Both Biomarker & Therapeutic Target in Prostate Cancer; Prostate Cancer KOL New Addition to Scientific Advisory Board
Aqualung Therapeutics, an early-stage biotech company developing an anti-inflammatory therapeutic platform for patients with serious unchecked inflammatory disease, has published proof of concept studies in EBio Medicine suggesting eNAMPT as a potential biomarker for the severity of invasive Prostate Cancer (PCa), and eNAMPT- neutralization as an effective therapeutic approach to limit PCa invasion and progression. Based on these findings, Aqualung has added Edwin M. Posadas MD, FACP to the Scientific Advisory Board.
Continue reading